External validation of triage tools for adults with suspected COVID-19 in a middle-income setting: an observational cohort study.


Journal

Emergency medicine journal : EMJ
ISSN: 1472-0213
Titre abrégé: Emerg Med J
Pays: England
ID NLM: 100963089

Informations de publication

Date de publication:
Jul 2023
Historique:
received: 05 09 2022
accepted: 04 05 2023
medline: 26 6 2023
pubmed: 23 5 2023
entrez: 22 5 2023
Statut: ppublish

Résumé

Tools proposed to triage ED acuity in suspected COVID-19 were derived and validated in higher income settings during early waves of the pandemic. We estimated the accuracy of seven risk-stratification tools recommended to predict severe illness in the Western Cape, South Africa. An observational cohort study using routinely collected data from EDs across the Western Cape, from 27 August 2020 to 11 March 2022, was conducted to assess the performance of the PRIEST (Pandemic Respiratory Infection Emergency System Triage) tool, NEWS2 (National Early Warning Score, version 2), TEWS (Triage Early Warning Score), the WHO algorithm, CRB-65, Quick COVID-19 Severity Index and PMEWS (Pandemic Medical Early Warning Score) in suspected COVID-19. The primary outcome was intubation or non-invasive ventilation, death or intensive care unit admission at 30 days. Of the 446 084 patients, 15 397 (3.45%, 95% CI 34% to 35.1%) experienced the primary outcome. Clinical decision-making for inpatient admission achieved a sensitivity of 0.77 (95% CI 0.76 to 0.78), specificity of 0.88 (95% CI 0.87 to 0.88) and the negative predictive value (NPV) of 0.99 (95% CI 0.99 to 0.99). NEWS2, PMEWS and PRIEST scores achieved good estimated discrimination (C-statistic 0.79 to 0.82) and identified patients at risk of adverse outcomes at recommended cut-offs with moderate sensitivity (>0.8) and specificity ranging from 0.41 to 0.64. Use of the tools at recommended thresholds would have more than doubled admissions, with only a 0.01% reduction in false negative triage. No risk score outperformed existing clinical decision-making in determining the need for inpatient admission based on prediction of the primary outcome in this setting. Use of the PRIEST score at a threshold of one point higher than the previously recommended best approximated existing clinical accuracy.

Sections du résumé

BACKGROUND BACKGROUND
Tools proposed to triage ED acuity in suspected COVID-19 were derived and validated in higher income settings during early waves of the pandemic. We estimated the accuracy of seven risk-stratification tools recommended to predict severe illness in the Western Cape, South Africa.
METHODS METHODS
An observational cohort study using routinely collected data from EDs across the Western Cape, from 27 August 2020 to 11 March 2022, was conducted to assess the performance of the PRIEST (Pandemic Respiratory Infection Emergency System Triage) tool, NEWS2 (National Early Warning Score, version 2), TEWS (Triage Early Warning Score), the WHO algorithm, CRB-65, Quick COVID-19 Severity Index and PMEWS (Pandemic Medical Early Warning Score) in suspected COVID-19. The primary outcome was intubation or non-invasive ventilation, death or intensive care unit admission at 30 days.
RESULTS RESULTS
Of the 446 084 patients, 15 397 (3.45%, 95% CI 34% to 35.1%) experienced the primary outcome. Clinical decision-making for inpatient admission achieved a sensitivity of 0.77 (95% CI 0.76 to 0.78), specificity of 0.88 (95% CI 0.87 to 0.88) and the negative predictive value (NPV) of 0.99 (95% CI 0.99 to 0.99). NEWS2, PMEWS and PRIEST scores achieved good estimated discrimination (C-statistic 0.79 to 0.82) and identified patients at risk of adverse outcomes at recommended cut-offs with moderate sensitivity (>0.8) and specificity ranging from 0.41 to 0.64. Use of the tools at recommended thresholds would have more than doubled admissions, with only a 0.01% reduction in false negative triage.
CONCLUSION CONCLUSIONS
No risk score outperformed existing clinical decision-making in determining the need for inpatient admission based on prediction of the primary outcome in this setting. Use of the PRIEST score at a threshold of one point higher than the previously recommended best approximated existing clinical accuracy.

Identifiants

pubmed: 37217302
pii: emermed-2022-212827
doi: 10.1136/emermed-2022-212827
pmc: PMC10359554
doi:

Types de publication

Observational Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

509-517

Subventions

Organisme : Bill & Melinda Gates Foundation
ID : INV-017293
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069911
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD080465
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Bill & Melinda Gates Foundation
ID : INV-004657
Pays : United States

Informations de copyright

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Lancet Glob Health. 2022 Jul;10(7):e961-e969
pubmed: 35597249
Ann Emerg Med. 2022 Jul;80(1):12-19
pubmed: 35339284
BMJ. 2015 Jan 07;350:g7594
pubmed: 25569120
J Investig Med. 2022 Apr;70(4):975-976
pubmed: 35086856
Thorax. 2003 May;58(5):377-82
pubmed: 12728155
PLoS Med. 2013;10(2):e1001381
pubmed: 23393430
Emerg Med J. 2022 Apr;39(4):317-324
pubmed: 35140074
BMC Health Serv Res. 2007 Mar 01;7:33
pubmed: 17328822
BMJ Qual Saf. 2022 Mar 30;:
pubmed: 35354665
Emerg Med J. 2022 Dec;39(12):918-923
pubmed: 35944968
BMJ Open. 2021 Jan 26;11(1):e047016
pubmed: 33500292
S Afr Med J. 2022 Feb 01;112(2):13496
pubmed: 35139985
Ann Emerg Med. 2020 Oct;76(4):442-453
pubmed: 33012378
Health Technol Assess. 2010 Oct;14(46):173-236
pubmed: 20923612
Int J Popul Data Sci. 2019 Nov 20;4(2):1143
pubmed: 32935043
PLoS One. 2021 Jan 22;16(1):e0245840
pubmed: 33481930
Eur Geriatr Med. 2020 Oct;11(5):829-841
pubmed: 32671732
PLoS Med. 2015 Oct 06;12(10):e1001885
pubmed: 26440803
PLoS One. 2020 Nov 25;15(11):e0240206
pubmed: 33237907
Am J Trop Med Hyg. 2021 Jan 06;104(3_Suppl):3-11
pubmed: 33410394
BMC Emerg Med. 2021 Oct 30;21(1):125
pubmed: 34715794
BMJ Open. 2021 Sep 15;11(9):e046130
pubmed: 34526332
Am J Emerg Med. 2021 Sep;47:213-216
pubmed: 33906127
BMC Med Ethics. 2021 Mar 22;22(1):28
pubmed: 33752662
Adv Anat Pathol. 2015 Sep;22(5):303-5
pubmed: 26262512
BMJ. 2020 Sep 9;370:m3339
pubmed: 32907855

Auteurs

Carl Marincowitz (C)

Centre for Urgent and Emergency Care Research (CURE), School of Health and Related Research (ScHARR), The University of Sheffield, Sheffield, UK c.marincowitz@sheffield.ac.uk.

Laura Sbaffi (L)

Information School, The University of Sheffield, Sheffield, UK.

Madina Hasan (M)

Centre for Urgent and Emergency Care Research (CURE), School of Health and Related Research (ScHARR), The University of Sheffield, Sheffield, UK.

Peter Hodkinson (P)

Division of Emergency Medicine, University of Cape Town Faculty of Health Sciences, Cape Town, South Africa.

David McAlpine (D)

Division of Emergency Medicine, University of Cape Town Faculty of Health Sciences, Cape Town, South Africa.

Gordon Fuller (G)

Centre for Urgent and Emergency Care Research (CURE), School of Health and Related Research (ScHARR), The University of Sheffield, Sheffield, UK.

Steve Goodacre (S)

Centre for Urgent and Emergency Care Research (CURE), School of Health and Related Research (ScHARR), The University of Sheffield, Sheffield, UK.

Peter A Bath (PA)

Centre for Urgent and Emergency Care Research (CURE), School of Health and Related Research (ScHARR), The University of Sheffield, Sheffield, UK.
Information School, The University of Sheffield, Sheffield, UK.

Yasein Omer (Y)

Division of Emergency Medicine, University of Cape Town Faculty of Health Sciences, Cape Town, South Africa.

Lee A Wallis (LA)

Division of Emergency Medicine, University of Cape Town Faculty of Health Sciences, Cape Town, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH